C4T Q2 2026 net loss $23.6M ($0.18/sh), cash $300.4M, cemsidomide trials on track

C4 Therapeutics, Inc.

Q2 2026 revenue $6.6M (vs $6.5M YoY); net loss $23.6M vs $26.0M; EPS -$0.18 vs -$0.37.
Cash, equivalents & securities $300.4M at Jun 30, 2026; funded to end of 2028.
Phase 2 MOMENTUM enrollment on track for Q1 2027; ORR data expected H2 2027.
Roche DAC collaboration: $20M upfront paid May 2026; new Phase 1b trial with daratumumab/carfilzomib to start H1 2027.
EHA 2026 data: ORR 40% at 75 µg and 53% at 100 µg doses in late-line MM; 2 MRD-negative patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.